Involvement of dopamine D1 and D2 receptors in the rat nucleus accumbens in immunostimulation

被引：6

作者：

Devoino L.V. ^{[1
]}

Al'perina E.L. ^{[1
]}

Gevorgyan M.M. ^{[1
]}

Cheido M.A. ^{[1
]}

机构：

[1] Research Institute of Physiology, Siberian Branch, Russian Academy of Medical Sciences, 630117 Novosibirsk

来源：

Neuroscience and Behavioral Physiology | 2007年 / 37卷 / 2期

基金：

俄罗斯基础研究基金会;

关键词：

Dopamine D[!sub]1[!/sub] and D[!sub]2[!/sub] receptors; Immunomodulation; Mesolimbic dopaminergic system; Nucleus accumbens; Quinpirol; SKF; 38393;

D O I：

10.1007/s11055-007-0162-9

中图分类号：

学科分类号：

摘要：

Analysis of the nature of changes in the immune response in operated Wistar rats showed that electrolytic lesioning of the nucleus accumbens, the site of the greatest density of dopamine D1 and D2 receptors, led to suppression of the immune response in animals immunized with sheep erythrocytes. Administration of SKF 38393 (20 mg/kg) and quinpirol (1 mg/kg), selective agonists of dopamine D1 and D2 receptors respectively, to sham-operated rats induced significant increases in immune responses. However, no immunostimulation was seen on administration of the selective dopamine D2 agonist quinpirol to animals with lesions to the nucleus accumbens as compared with controls. At the same time, treatment of animals with nucleus accumbens lesions using the dopamine D1 receptor agonist SKF 38393 had no effect on the immune response as compared with that in sham-operated animals given the D1 receptor agonist. These data provide evidence that dopamine D2 receptors in the nucleus accumbens have a role in the mechanisms of immunostimulation, though D2 receptors in other brain structures may also make some contribution to this process; D1 receptors in the nucleus accumbens make no significant contribution to controlling the immune response. © Springer Science+Business Media, Inc. 2007.

引用

页码：147 / 151

页数：4

共 25 条

[11]

Ariano M.A., Sibley D.R., Dopamine receptor distribution in the rat CNS: Elucidation using anti-peptide antisera directed against D<sub>1</sub>A and D<sub>3</sub> subtypes, Brain Res. Bull., 649, 1-2, pp. 95-110, (1994)

[12]

Carlsson M., Carlsson A., Schizophrenia: A subcortical neurotransmitter imbalance syndrome?, Schizophr. Bull., 16, pp. 426-432, (1990)

[13]

Cunningham A.J., A method of increased sensitivity for detecting single antibody-forming cells, Nature, 207, pp. 1106-1107, (1965)

[14]

Devoino L., Idova G., Alperina E., Cheido M., Brain neuromediator systems in the immune response control: Pharmacological analysis of pre-and postsynaptic mechanisms, Brain Res., 633, pp. 267-274, (1994)

[15]

Devoino L.V., Alperina E.L., Galkina O.V., Ilyutchenok R.Yu., Involvement of brain dopaminergic structures in neuroimmunomodulation, Internat. J. Neurosci., 91, 3-4, pp. 213-228, (1997)

[16]

Holden R.G., Pakula I.S., Mooney P.A., A neuroimmunological model of schizophrenia and major depression: A review, J. Human Psychopharmacology, 12, pp. 177-201, (1997)

[17]

Konig J.F.R., Klippel R.A., The Rat Brain. A Stereotaxic Atlas of the Forebrain and Low Parts of the Brain Stem, (1963)

[18]

Kopin I.J., Neurotransmitters and disorders of the basal ganglia, Basic Neurochemistry: Molecular, Cellular and Medical Aspects, pp. 899-918, (1994)

[19]

Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G., Dopamine receptors: From Structure to function, Physiol. Rev., 78, 1, pp. 196-214, (1998)

[20]

Muller N., Riedel M., Gruber R., Ackenheil M., Scharz M.J., The immune system and schizophrenia: An integrative view, Ann. N.Y. Acad. Sci., 917, pp. 456-467, (2000)

← 1 2 3 →